Patent 10123998 was granted and assigned to Plexxikon Inc. on November, 2018 by the United States Patent and Trademark Office.
The present disclosure provides methods of using protein kinase inhibitors for treating diseases and conditions, including diseases and conditions associated with activity of any protein kinase selected from Fms protein kinase including any mutations thereof, Kit protein kinase any mutations thereof, Flt-3 protein kinase any mutations thereof and combinations thereof.